亞盛醫藥(06855.HK)在研原創新藥在歐洲臨床研究完成首例患者給藥
亞盛醫藥-B(06855.HK)公布,公司在研原創1類新藥Bcl-2抑制劑APG-2575作為單藥或聯合治療復發/難治慢性淋巴細胞白血病(CLL)/小淋巴細胞淋巴瘤(SLL)的Ib/II期臨床研究(編號:APG2575CU101;EudraCT註冊號:2020–002736–73),已在烏克蘭完成首例患者給藥。這是亞盛醫藥在歐洲開展的首項全球臨床試驗。
該項研究為一項國際多中心的Ib/II期臨床研究,旨在評估APG-2575單藥或聯合治療復發╱難治CLL/SLL患者的療效和安全性,現已獲得烏克蘭衛生部和俄羅斯衛生部批准展開臨床試驗(CTA)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.